Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR mHealth and uHealth

Date Submitted: Aug 2, 2020
Date Accepted: Oct 22, 2020
Date Submitted to PubMed: Oct 23, 2020

The final, peer-reviewed published version of this preprint can be found here:

Myofunctional Therapy App for Severe Apnea–Hypopnea Sleep Obstructive Syndrome: Pilot Randomized Controlled Trial

O'Connor-Reina C, Ignacio-Garcia JM, Rodriguez-Ruiz E, Morillo Dominguez MDC, Ignacio Barrios V, Casado Morente JC, Plaza G, Baptista Jardin P, Garcia Iriarte MT

Myofunctional Therapy App for Severe Apnea–Hypopnea Sleep Obstructive Syndrome: Pilot Randomized Controlled Trial

JMIR Mhealth Uhealth 2020;8(11):e23123

DOI: 10.2196/23123

PMID: 33093013

PMCID: 7683258

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Myofunctional Therapy App for Severe Apnea–Hypopnea Sleep Obstructive Syndrome: A Randomized prospective trial-

  • Carlos O'Connor-Reina; 
  • Jose Maria Ignacio-Garcia; 
  • Elisa Rodriguez-Ruiz; 
  • Maria Del Carmen Morillo Dominguez; 
  • Victoria Ignacio Barrios; 
  • Juan Carlos Casado Morente; 
  • Guillermo Plaza; 
  • Peter Baptista Jardin; 
  • Maria Teresa Garcia Iriarte

ABSTRACT

Background:

Rationale: Myofunctional therapy has demonstrated efficacy for treating sleep-disordered breathing. We assessed the clinical use of a new mobile health (mHealth) app that teaches patients with severe obstructive sleep apnea–hypopnea syndrome (OSAHS) to perform oropharyngeal exercises using their smartphone.

Objective:

To examine the effects of the app in patients with severe OSAHS

Methods:

Forty patients with severe OSAHS (apnea–hypoxia index (AHI) > 30) were enrolled prospectively and randomized into an intervention group that used the app for 90 sessions or a control group. Anthropometric measures, Epworth Sleepiness Scale (0–24), Pittsburgh Sleep Quality Index (0–21), and Iowa Oral Performance Instrument (IOPI) scores, O2 desaturation index, were obtained before and after the intervention.

Results:

: After the intervention, 28 patients remained. No significant changes were observed in the control group. The intervention group showed significant improvements. AHI decreased 53.36% from 44.7 (33.8–55.6) to 20.88 (14.02–27.7) events/h (P < 0.00001). Oxygen desaturation index decreased 46.5% from 36.31 (27.19–43.43) to 19.4 (12.9–25.98) events/h (P = 0.003). IOPI maximum tongue score increased from 39.83 (35.32–45.20) to 59.06 (54.74–64.00) kPa (P = 0.0001). IOPI maximum lip score increased from 27.89 (24.16–32.47) to 44.11 (39.5–48.80) kPa (P = 0.0003). The AHI correlated significantly with IOPI tongue and lip improvements (Pearson –0.560, P = 0.00001 and –0.460, P = 0.0001, respectively).

Conclusions:

Orofacial exercises performed using an mHealth app reduce OSAHS severity and symptoms, and represent a promising treatment for OSAHS. Clinical Trial: Spanish Gov identifier: AWGAPN-2019-01 ClinicalTrials.gov Identifier: NCT04438785


 Citation

Please cite as:

O'Connor-Reina C, Ignacio-Garcia JM, Rodriguez-Ruiz E, Morillo Dominguez MDC, Ignacio Barrios V, Casado Morente JC, Plaza G, Baptista Jardin P, Garcia Iriarte MT

Myofunctional Therapy App for Severe Apnea–Hypopnea Sleep Obstructive Syndrome: Pilot Randomized Controlled Trial

JMIR Mhealth Uhealth 2020;8(11):e23123

DOI: 10.2196/23123

PMID: 33093013

PMCID: 7683258

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.